According to data collected by the American Cancer Society, 70 percent of smokers want to quit altogether, 7 percent actually succeed at quitting smoking their first time, and 3.5 percent quit smoking cold turkey. These statistics are already extremely unsettling. Even though 40 percent of smokers tried to quit in 2015, half of smokers will relapse into smoking while intoxicated with alcohol.
These statistics even come into play with individuals who are underage. According to data collected by the Centers for Disease Control, 80 percent of smokers began smoking before the age of 18, while 90 percent began smoking before the age of 21. 3,900 teens begin smoking each day, totaling 600,000 teens each year. What’s disturbing is that 11 percent of middle school students reported having smoked. That means 11 percent of pre-teens between the ages of 11 and 14.
A successful vaccine to assist individuals in quitting smoking for good has been difficult to discover. According to a report in ACS’s Journal of Medicinal Chemistry, a new vaccine for quitting smoking has been designed.
Over half of smokers who want to quit will not succeed in quitting their first time. There are several ways to quit smoking available. Smokers can quit cold turkey, use behavioral therapy, nicotine replacement therapy (nicotine gum, patches, inhalers, spray, and lozenges), and medicine like Zyban and Chantix. These tools are readily available, but aren’t always effective, and may even have undesirable side effects.
This new vaccine design would target the nicotine molecule directly. Two individuals participated in a clinical study of the vaccine which ultimately failed. However, the clinical study provided worthwhile pieces of information, that scientists could improve upon.
The trials indicated that the individuals who produced the most elevated amounts of anti-nicotine antibodies were more likely to refrain from smoking for more than six months. Kim D. Janda, Ph.D., and fellow researchers from The Scripps Research Institute wanted to expand on this discovery.
The team designed a new vaccine that could raise the amount of antibodies that could attach to nicotine molecules.
While testing in mice, they discovered that the vaccine deferred the effects of nicotine after injection within the initial 10 minute period. Additionally, they discovered that the mice treated with the vaccine had lower concentrations of nicotine in their brains, which is where nicotine has its effects. The team expressed that their future endeavors will concentrate on further perfecting the formula of the vaccine to prepare it for potential clinical studies.